Literature DB >> 33080212

Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials.

Dimitrios Patoulias1, Maria Toumpourleka2, Christodoulos Papadopoulos3, Michael Doumas4.   

Abstract

Entities:  

Year:  2020        PMID： 33080212     DOI： 10.1016/j.amjcard.2020.10.030

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  3 in total

1.  SGLT-2 Inhibitors Beneficial Effects on Ventricular Repolarization May Be Protective against Atrial Fibrillation Occurrence.

Authors:  Dimitrios Patoulias
Journal:  Acta Cardiol Sin       Date:  2021-05       Impact factor: 2.672

2.  Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes.

Authors:  Angeliki Bourazana; Grigorios Giamouzis; John Skoularigis; Filippos Triposkiadis; Andrew Xanthopoulos
Journal:  World J Cardiol       Date:  2022-04-26

3.  Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?

Authors:  Sahith Reddy Thotamgari; Udhayvir Singh Grewal; Aakash R Sheth; Akhilesh Babbili; Paari Dominic
Journal:  Cardiovasc Endocrinol Metab       Date:  2022-06-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.